Close Menu

Warfarin will soon have a label saying that people with certain genetic variations should start off with a lower initial dose of the blood thinner, reports the Wall Street Journal. Adding this label is part of the Food and Drug Administration's push to promote using genetics to predict patient's reactions to medicine, a major tenet of personalized medicine.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.